Work with your healthcare provider to create a personalized meal plan that supports your blood sugar control and weight loss goals
These are gaps in the research record, not established safety findings
None of GHK-Cu, BPC-157, or TB-500 has an approved human indication, and the GLOW combination specifically has no clinical trial establishing safety or efficacy in humans
GLP-1 users prioritize protein per bite and favor high fiber, while shunning sugar and seeking small serving sizes, healthy snacks, and new beverages
Agier J, Brzezinska-Blaszczyk E, Zelechowska P, Wiktorska M, Pietrzak J, Rozalska S (2018) Cathelicidin LL-37 Affects Surface and Intracellular Toll-Like Receptor Expression in Tissue Mast Cells
Applied for a smaller group Novo Nordisk had applied for a subsidy for Wegovy for a defined patient group with a very high body mass index (BMI) and several concomitant diseases